Evolus 

€14.8
27
-€0.3-1.99% 今天

统计数据

当日最高
14.8
当日最低
14.8
52周最高
-
52周最低
-
成交量
0
平均成交量
-
市值
994.77M
市盈率
-
股息收益率
-
股息
-

即将到来

收益

5Nov预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
-0.32
-0.23
-0.13
-0.04
预期每股收益
-0.1237
实际每股收益
N/A

人们还关注

此列表基于关注EVL.F的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Show more...
首席执行官
Mr. David Moatazedi
员工
304
国家
US
ISIN
US30052C1071
WKN
000A2JDYX

上市公司